Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. That data is a lagging indicator, especially as filings are not required immediately at the end of each quarter.
The data is available via our Psychedelics Federal Lobbying Tracker. Below is our analysis of the latest developments for our Pα+ subscribers. Here’s a review of Q3 2025 activity…
Drug Developers’ Federal Lobbying Spend Reaches New High
In aggregate, federal lobbying spend among psychedelic drug developers has reached a new high in Q3’25, with a modest increase over previous quarters this year.
That record comes in spite of Lykos Therapeutics’ decision to terminate its federal lobbying spend, according to filings. Over the past two years, Lykos had been the biggest spender on such efforts, which was unsurprising given that it was the first developer to attempt to score FDA approval…
To continue reading, please log in or join Pα+…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
